Weight gain, body composition, and metabolic parameters of dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: an ancillary analysis of the ODYSSEY trial
Authors:
Open Access
- 21 January 2026
- journal article
- research article
- Published by Elsevier in The Lancet Child & Adolescent Health
- Vol. 10 (3) , 189-202
Abstract
No abstract availableKeywords
Funding Information
- UK Research and Innovation Medical Research Council (MC_UU_00004/03)
This publication has 28 references indexed in Scilit:
- Second-Line Antiretroviral Therapy for Children Living with HIV in AfricaNew England Journal of Medicine, 2025
- Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021The Lancet, 2025
- Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV – Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trialeClinicalMedicine, 2023
- Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trialThe Lancet HIV, 2022
- Evidence synthesis evaluating body weight gain among people treating HIV with antiretroviral therapy - a systematic literature review and network meta-analysiseClinicalMedicine, 2022
- Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in ChildrenNew England Journal of Medicine, 2021
- Transition to Dolutegravir Is Associated With an Increase in the Rate of Body Mass Index Change in a Cohort of Virally Suppressed AdolescentsClinical Infectious Diseases, 2020
- Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in CameroonThe Lancet HIV, 2020
- Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trialThe Lancet HIV, 2020
- Body fat reference curves for childrenInternational Journal of Obesity, 2006